Teva Pharma (NYSE: TEVA) reported Q3 EPS of $0.69, $0.03 better than the analyst estimate of $0.66. Revenue for the quarter came in at $4.3 billion versus the consensus estimate of $4.14 billion.

GUIDANCE:

Teva Pharma sees FY2024 EPS of $2.40-$2.50, versus the consensus of $2.45. Teva Pharma sees FY2024 revenue of $16.1-16.5 billion, versus the consensus of $16.262 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.